163 related articles for article (PubMed ID: 33235070)
21. Therapeutic and cost effectiveness of proton pump inhibitor regimens for idiopathic or drug-induced peptic ulcer complication.
Nam DH; Park SY; Park JM; Kim SC
Arch Pharm Res; 2011 Mar; 34(3):443-9. PubMed ID: 21547676
[TBL] [Abstract][Full Text] [Related]
22. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
[TBL] [Abstract][Full Text] [Related]
23. Rabeprazole Coadministration Controls Ulcer Recurrence in Patients on Low-dose Aspirin Therapy: A Multicenter Prospective Study.
Kinoshita Y; Kato M; Sugizaki K; Ikeuchi S
Intern Med; 2023 Feb; 62(4):495-502. PubMed ID: 35908971
[TBL] [Abstract][Full Text] [Related]
24. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Edwards SJ; Lind T; Lundell L
Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
[TBL] [Abstract][Full Text] [Related]
25. New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China.
Ren L; Lu H; Li HY; Zhu LY; Xu XQ; Gu LY; Ge ZZ; Li XB
J Dig Dis; 2014 Nov; 15(11):622-7. PubMed ID: 25205201
[TBL] [Abstract][Full Text] [Related]
26. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Haddad I; Kierkus J; Tron E; Ulmer A; Hu P; Sloan S; Silber S; Leitz G
J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):798-807. PubMed ID: 23863328
[TBL] [Abstract][Full Text] [Related]
28. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?
Gisbert JP; Pajares JM
Aliment Pharmacol Ther; 2005 Apr; 21(7):795-804. PubMed ID: 15801914
[TBL] [Abstract][Full Text] [Related]
29. Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.
Shu X; Zhu Z; Fu Y; Zhang Z; Wang J; Li X; He S; Fan H; Liu S; Zhang G; Tang J; Huang C; Du Q; Wang X; Xu B; Du Y; Chen Q; Wang B; Chen Y; Duan X; Xie Y; Huo L; Hou X; Lu N
Front Med (Lausanne); 2021; 8():690995. PubMed ID: 34336894
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
[TBL] [Abstract][Full Text] [Related]
31. Allicin as add-on therapy for
Si XB; Zhang XM; Wang S; Lan Y; Zhang S; Huo LY
World J Gastroenterol; 2019 Oct; 25(39):6025-6040. PubMed ID: 31660038
[TBL] [Abstract][Full Text] [Related]
32. [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].
Lin SR;
Zhonghua Nei Ke Za Zhi; 2005 Apr; 44(4):265-7. PubMed ID: 15924638
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of proton pump inhibitors (PPIs) plus rebamipide for endoscopic submucosal dissection-induced ulcers: a meta-analysis.
Wang J; Guo X; Ye C; Yu S; Zhang J; Song J; Cao Z; Wang J; Liu M; Dong W
Intern Med; 2014; 53(12):1243-8. PubMed ID: 24930641
[TBL] [Abstract][Full Text] [Related]
34. Xiao Chai Hu Tang for Peptic Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Li M; Dan W; Zhang H; Yun Y; He Q
Evid Based Complement Alternat Med; 2021; 2021():6693677. PubMed ID: 34012475
[TBL] [Abstract][Full Text] [Related]
35. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials.
Hu ZH; Shi AM; Hu DM; Bao JJ
Saudi J Gastroenterol; 2017; 23(1):11-19. PubMed ID: 28139495
[TBL] [Abstract][Full Text] [Related]
37. Mechanistic evaluation of gastroprotective effects of Kangfuxin on ethanol-induced gastric ulcer in mice.
Shen Y; Sun J; Niu C; Yu D; Chen Z; Cong W; Geng F
Chem Biol Interact; 2017 Aug; 273():115-124. PubMed ID: 28606470
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
39. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
[TBL] [Abstract][Full Text] [Related]
40. The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer: a randomized controlled trial.
Nakamura M; Tahara T; Shiroeda H; Matsunaga K; Otsuka T; Yonemura J; Shibata T; Arisawa T
Hepatogastroenterology; 2015; 62(137):219-24. PubMed ID: 25911899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
